Abstracts tagged "Inclusion body myositis"

Abstract Number: 0692 • ACR Convergence 2021
Immunophenotyping of Inclusion Body Myositis Blood T Cells: Pathogenic and Biomarker Implications
Namita Goyal¹, Jonathan Cauchi¹, Tyler Irani¹, Nadia Araujo¹, Leo Wang², Marie Wencel¹, Vivian Li³, Steven Greenberg⁴ and Tahseen Mozaffar¹, ¹University of California Irvine, Irvine, CA, ²University of Washington, Seattle, WA, ³University of California, Irvine, CA, ⁴Brigham and Women's Hospital Department of Neurology, Boston, MA
Background/Purpose: The recent discovery of highly differentiated, killer cell lectin-like receptor subfamily G member 1 (KLRG1)+ T cells in the muscle of inclusion body myositis…
Abstract Number: 1289 • 2019 ACR/ARP Annual Meeting
Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features
Antonella Notarnicola¹, Francesco Bonomi ², Cecilia Hellstrom ³, Elisa Pin ³, Helena Idborg ¹, Peter Nilsson ⁴ and Ingrid E Lundberg ¹, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Vita-Salute San Raffaele University, Milano, Italy, ³Affinity Proteomics, SciLifeLab, Department of Protein Science, KTH - Royal Institute of Technology, Stockholm, Sweden, ⁴Science for Life Laboratory, Affinity Proteomics; KTH − Royal Institute of Technology, School of Biotechnology;Stockholm (Sweden), Stockholm, Sweden
Background/Purpose: Antibodies to cytosolic 5’-Nucleotidase 1A (anti-cN1A or NT5C1A) are considered the only currently known serum biomarker for sporadic Inclusion Body Myositis (sIBM). They are…
Abstract Number: 2308 • 2016 ACR/ARHP Annual Meeting
Thigh Muscle MRI Reveals Extensive Muscle Edema and Early Fatty Replacement in Patients with Immune-Mediated Necrotizing Myopathy
Iago Pinal-Fernandez¹, Maria Casal-Dominguez², John A. Carrino³, Arash Lahoutiharahdashti², Pari Basharat⁴, Jemima Albayda², Julie J. Paik², Shivani Ahlawat⁵, Sonye K. Danoff⁶, Thomas E. Lloyd⁷, Andrew Mammen⁸ and Lisa Christopher-Stine⁶, ¹Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, University of Western Ontario, London, ON, Canada, ⁵Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Neurology, Johns Hopkins, Baltimore, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: The aim of this study was to define the pattern of muscle involvement in patients with immune-mediated necrotizing myopathy (IMNM). Methods: All Johns Hopkins…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].